Brother Enterprises (SHE:002562) subsidiary Jiangxi Brother Pharmaceutical obtained the registration certificate for its iodixanol active pharmaceutical ingredient from India's Central Drugs Standard Control Organisation.

The certificate, valid until April 28, 2029, allows the company to officially market and sell the iodine contrast agent API in India, according to a Friday filing with the Shenzhen bourse.

Iodixanol is used as a contrast agent during coronary angiography.